Stay updated with breaking news from Preserved Ejection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MATERIAL CHANGE REPORT - Name and Address of Company Cardiol Therapeutics Inc. 2265 Upper Middle Road East, Suite 602 Oakville, Ontario,...
Cardiol Therapeutics Inc. , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart...
Robert J. Mentz, MD, and Javed Butler, MD, MPH, MBA, comment on the use of beta blockers and other agents in patients with heart failure preserved ejection fraction (HFpEF).
This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.
AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin in Great Britain for the treatment of symptomatic chronic heart failure (HF) in patients with HF and a left ventricular ejection fraction (LVEF)